Linkedin
RLS logo_header
Linkedin

NMPA approves toripalimab combined with bevacizumab for 1L treatment of HCC in China

Dr. Jianjun Zou, General Manager and CEO of Junshi Biosciences, said: “Based on the ‘Ten Perfections’, Toripalimab continues to make breakthroughs and has been officially approved for its 11th indication, which makes us very excited! As the country with the heaviest burden of liver cancer in the world, liver cancer patients in China have long faced the dilemma of limited treatment options. Junshi Biosciences has long focused on the clinical needs in the field of liver cancer treatment worldwide, and has arranged clinical studies using multi-combination strategies for different disease course populations, aiming to provide liver cancer patients with more accurate and richer treatment options. We will continue to be committed to drug innovation in this field and inject more powerful ‘Chinese wisdom’ into the fight against liver cancer.”

Read the full story on "NMPA approves toripalimab combined with bevacizumab for 1L treatment of HCC in China"

Share:

More News

Gotistobart Nearly Doubled Median OS versus SOC Chemo in Previously Treated Squamous NSCLC Patients

“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel

Ratio Therapeutics Enters into Research Collaboration and License Agreement with RayzeBio to Advance a Novel Radiopharmaceutical Program

“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated

Zipalertinib + chemo Demonstrates 6-Month Median PFS Benefit in REZILIENT3 Ph 3 Trial in 1L EGFR Exon 20 Insertion Mutation NSCLC

“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with

FDA clears IND application to initiate Ph 1 study for PRT13722 for HR+/HER2- breast cancer patients

“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines